VM26: phase I and II studies

Review

F R Macbeth. Cancer Chemother Pharmacol. 1982.

. 1982;7(2-3):87-91.

doi: 10.1007/BF00254527.

No abstract available

Similar articles

Phase II study of VM-26 in adult malignancies.
Spremulli E, Schulz JJ, Speckhart VJ, Wampler GL. Spremulli E, et al. Cancer Treat Rep. 1980 Jan;64(1):147-9. Cancer Treat Rep. 1980. PMID: 7379049 No abstract available.
The podophyllotoxin derivatives VP16-213 and VM26.
Issell BF. Issell BF. Cancer Chemother Pharmacol. 1982;7(2-3):73-80. doi: 10.1007/BF00254525. Cancer Chemother Pharmacol. 1982. PMID: 7044593 Review.
Teniposide (VM26) as second-line treatment for small cell lung cancer.
Tummarello D, Guidi F, Torresi U, Dazzi C, Cellerino R. Tummarello D, et al. Anticancer Res. 1990 Mar-Apr;10(2A):397-9. Anticancer Res. 1990. PMID: 2161198
Phase II trial of teniposide in previously treated and untreated patients with advanced colorectal carcinoma: an Illinois Cancer Council Trial.
Locker GY, Lanzotti V, Khandekar JD, Sweet D, Shaw J, Bitran J, Gordon L, Krauss S, Johnson C. Locker GY, et al. Cancer Treat Rep. 1986 Feb;70(2):307-8. Cancer Treat Rep. 1986. PMID: 3948195 No abstract available.
A phase II study with teniposide (VM26) in patients with progressed or relapsed small cell lung cancer (SCLC).
Tummarello D, Guidi F, Di Furia L, Gramazio A, Menichetti E, Cellerino R. Tummarello D, et al. J Chemother. 1989 Feb;1(1):64-7. doi: 10.1080/1120009x.1989.11738866. J Chemother. 1989. PMID: 2542470 Review.

The clinical pharmacology of etoposide and teniposide.
Clark PI, Slevin ML. Clark PI, et al. Clin Pharmacokinet. 1987 Apr;12(4):223-52. doi: 10.2165/00003088-198712040-00001. Clin Pharmacokinet. 1987. PMID: 3297462 Review.